Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Ann Surg ; 265(6): 1241-1249, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-27232244

RESUMEN

OBJECTIVE: The aim of this study was to measure neutrophil function longitudinally following burn injury and to examine the relationship between neutrophil dysfunction and sepsis. BACKGROUND: Sepsis prevalence and its associated mortality is high following burn injury, and sepsis diagnosis is complicated by the ongoing inflammatory response. Previous studies have suggested that neutrophil dysfunction may underlie high infection rates and sepsis postburn; however, neutrophil dysfunction has not been thoroughly characterized over time in burns patients. METHODS: Neutrophil phagocytosis, oxidative burst capacity, and neutrophil extracellular trap (NET) generation (NETosis) were measured from 1 day to up to 1 year postburn injury in 63 patients with major burns (≥15% total body surface area). In addition, immature granulocyte (IG) count, plasma cell-free DNA (cfDNA), and plasma citrullinated histone H3 (Cit H3) levels were measured. RESULTS: Neutrophil function was reduced for 28 days postburn injury and to a greater degree in patients who developed sepsis, which was also characterized by elevated IG counts. Plasma cfDNA and Cit-H3, a specific marker of NETosis, were elevated during septic episodes. The combination of neutrophil phagocytic capacity, plasma cfDNA levels, and IG count at day 1 postinjury gave good discriminatory power for the identification of septic patients. CONCLUSION: Neutrophil function, IG count, and plasma cfDNA levels show potential as biomarkers for the prediction/early diagnosis of sepsis postburn injury and neutrophil dysfunction may actively contribute to the development of sepsis. Targeting neutrophil dysfunction and IG release may be a viable therapeutic intervention to help reduce the incidence of nosocomial infections and sepsis postburn.


Asunto(s)
Quemaduras/complicaciones , ADN/sangre , Granulocitos , Neutrófilos/fisiología , Sepsis/diagnóstico , Biomarcadores/sangre , Infección Hospitalaria/diagnóstico , Histonas/sangre , Humanos , Recuento de Leucocitos , Fagocitosis , Estudios Prospectivos , Estallido Respiratorio
2.
Burns ; 44(2): 288-297, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29032970

RESUMEN

BACKGROUND: Platelet cells, or thrombocytes, have additional roles to haemostasis. After burn injury, platelet counts drop to a nadir at days 2-5 then rise to a peak between days 10-18. The nadir has previously been associated with mortality but there is currently no thorough investigation of its potential to predict sepsis in adults. The primary objective of this study is to assess whether platelet count can predict survival and sepsis in adults with severe burn injuries. METHODS AND FINDINGS: A retrospective cohort analysis of platelet count and other blood parameters in 145 burn patients with a TBSA greater than 20%. AUROC analysis revealed that the platelet count and rBaux score together produce moderate discrimination for survival at less than 24h after injury (AUROC=0.848, 95%CI 0.765-0.930). Platelet count at day 3 combined with TBSA has a modest association with sepsis (AUROC=0.779, 95%CI 0.697-0.862). Multivariable Cox regression analysis revealed platelet peak was the strongest predictor of mortality. CONCLUSIONS: A reduced peak platelet count is a strong predictor of 50-day mortality. Platelet count nadir may have some association with sepsis.


Asunto(s)
Quemaduras/sangre , Recuento de Plaquetas , Sepsis/sangre , Adulto , Anciano , Área Bajo la Curva , Quemaduras/mortalidad , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Modelos de Riesgos Proporcionales , Curva ROC , Estudios Retrospectivos , Sepsis/epidemiología , Índices de Gravedad del Trauma
3.
Blood Adv ; 2(3): 240-251, 2018 02 13.
Artículo en Inglés | MEDLINE | ID: mdl-29437639

RESUMEN

Soluble glycoprotein VI (sGPVI) is shed from the platelet surface and is a marker of platelet activation in thrombotic conditions. We assessed sGPVI levels together with patient and clinical parameters in acute and chronic inflammatory conditions, including patients with thermal injury and inflammatory bowel disease and patients admitted to the intensive care unit (ICU) for elective cardiac surgery, trauma, acute brain injury, or prolonged ventilation. Plasma sGPVI was measured by enzyme-linked immunosorbent assay and was elevated on day 14 after thermal injury, and was higher in patients who developed sepsis. sGPVI levels were associated with sepsis, and the value for predicting sepsis was increased in combination with platelet count and Abbreviated Burn Severity Index. sGPVI levels positively correlated with levels of D-dimer (a fibrin degradation product) in ICU patients and patients with thermal injury. sGPVI levels in ICU patients at admission were significantly associated with 28- and 90-day mortality independent of platelet count. sGPVI levels in patients with thermal injury were associated with 28-day mortality at days 1, 14, and 21 when adjusting for platelet count. In both cohorts, sGPVI associations with mortality were stronger than D-dimer levels. Mechanistically, release of GPVI was triggered by exposure of platelets to polymerized fibrin, but not by engagement of G protein-coupled receptors by thrombin, adenosine 5'-diphosphate, or thromboxane mimetics. Enhanced fibrin production in these patients may therefore contribute to the observed elevated sGPVI levels. sGPVI is an important platelet-specific marker for platelet activation that predicts sepsis progression and mortality in injured patients.


Asunto(s)
Fibrina/fisiología , Inflamación/sangre , Activación Plaquetaria , Glicoproteínas de Membrana Plaquetaria/análisis , Valor Predictivo de las Pruebas , Biomarcadores/sangre , Quemaduras/sangre , Quemaduras/mortalidad , Quemaduras/patología , Progresión de la Enfermedad , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Humanos , Inflamación/mortalidad , Enfermedades Inflamatorias del Intestino/sangre , Enfermedades Inflamatorias del Intestino/mortalidad , Enfermedades Inflamatorias del Intestino/patología , Mortalidad , Recuento de Plaquetas , Glicoproteínas de Membrana Plaquetaria/metabolismo , Sepsis/sangre , Sepsis/mortalidad , Sepsis/patología , Solubilidad
4.
Genetics ; 160(1): 75-82, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11805046

RESUMEN

Mitochondrial translation is largely membrane-associated in S. cerevisiae. Recently, we discovered that the matrix protein Nam1p binds the amino-terminal domain of yeast mtRNA polymerase to couple translation and/or RNA-processing events to transcription. To gain additional insight into these transcription-coupled processes, we performed a genetic screen for genes that suppress the petite phenotype of a point mutation in mtRNA polymerase (rpo41-R129D) when overexpressed. One suppressor identified in this screen was SLS1, which encodes a mitochondrial membrane protein required for assembly of respiratory-chain enzyme complexes III and IV. The mtRNA-processing defects associated with the rpo41-R129D mutation were corrected in the suppressed strain, linking Sls1p to a pathway that includes mtRNA polymerase and Nam1p. This was supported by the observation that SLS1 overexpression rescued the petite phenotype of a NAM1 null mutation. In contrast, overexpression of Nam1p did not rescue the petite phenotype of a SLS1 null mutation, indicating that Nam1p and Sls1p are not functionally redundant but rather exist in an ordered pathway. On the basis of these data, a model in which Nam1p coordinates the delivery of newly synthesized transcripts to the membrane, where Sls1p directs or regulates their subsequent handling by membrane-bound factors involved in translation, is proposed.


Asunto(s)
Proteínas Portadoras/fisiología , ADN Mitocondrial/genética , Proteínas Fúngicas , Regulación Fúngica de la Expresión Génica/fisiología , Proteínas de la Membrana/fisiología , Mitocondrias/genética , Proteínas de Saccharomyces cerevisiae/fisiología , Saccharomyces cerevisiae/genética , Apoproteínas/metabolismo , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Grupo Citocromo b/metabolismo , Citocromos b , ARN Polimerasas Dirigidas por ADN/metabolismo , Expresión Génica/fisiología , Proteínas de la Membrana/genética , Proteínas Mitocondriales , ARN/metabolismo , ARN de Hongos/metabolismo , ARN Mitocondrial , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Factores de Transcripción/metabolismo , Transcripción Genética
5.
PLoS One ; 10(9): e0136190, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26352256

RESUMEN

INTRODUCTION: Localised infections, and burn wound sepsis are key concerns in the treatment of burns patients, and prevention of colonisation largely relies on biocides. Acetic acid has been shown to have good antibacterial activity against various planktonic organisms, however data is limited on efficacy, and few studies have been performed on biofilms. OBJECTIVES: We sought to investigate the antibacterial activity of acetic acid against important burn wound colonising organisms growing planktonically and as biofilms. METHODS: Laboratory experiments were performed to test the ability of acetic acid to inhibit growth of pathogens, inhibit the formation of biofilms, and eradicate pre-formed biofilms. RESULTS: Twenty-nine isolates of common wound-infecting pathogens were tested. Acetic acid was antibacterial against planktonic growth, with an minimum inhibitory concentration of 0.16-0.31% for all isolates, and was also able to prevent formation of biofilms (at 0.31%). Eradication of mature biofilms was observed for all isolates after three hours of exposure. CONCLUSIONS: This study provides evidence that acetic acid can inhibit growth of key burn wound pathogens when used at very dilute concentrations. Owing to current concerns of the reducing efficacy of systemic antibiotics, this novel biocide application offers great promise as a cheap and effective measure to treat infections in burns patients.


Asunto(s)
Ácido Acético/farmacología , Bacterias/efectos de los fármacos , Biopelículas/efectos de los fármacos , Quemaduras/microbiología , Desinfectantes/farmacología , Bacterias/aislamiento & purificación , Bacterias/patogenicidad , Infección Hospitalaria/microbiología , Evaluación Preclínica de Medicamentos , Humanos , Pruebas de Sensibilidad Microbiana , Factores de Tiempo , Infección de Heridas/prevención & control
6.
Burns ; 41(8): 1683-1694, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26188884

RESUMEN

UNLABELLED: Antimicrobial medicated dressings (AMD) are often used to reduce bacterial infection of burns and other wounds. However, there is limited literature regarding comparative efficacies to inform effective clinical decision making. OBJECTIVES: Following on from a previous study where we demonstrated good antibiofilm properties of acetic acid (AA), we assessed and compared the in vitro anti-biofilm activity of a range of AMDs and non-AMDs to AA. METHODS: Laboratory experiments determined the ability of a range of eleven commercial AMD, two nAMD, and AA, to prevent the formation of biofilms of a panel of four isolates of Pseudomonas aeruginosa and Acinetobacter baumannii. RESULTS: There is a large variation in ability of different dressings to inhibit biofilm formation, seen between dressings that contain the same, and those that contain other antimicrobial agents. The best performing AMD were Mepilex(®) Ag and Acticoat. AA consistently prevented biofilm formation. CONCLUSIONS: Large variation exists in the ability of AMD to prevent biofilm formation and colonisation of wounds. A standardised in vitro methodology should be developed for external parties to examine and compare the efficacies of commercially available AMDs, along with robust clinical randomised controlled trials. This is essential for informed clinical decision-making and optimal patient management.


Asunto(s)
Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Vendajes , Biopelículas/efectos de los fármacos , Quemaduras/terapia , Pseudomonas aeruginosa/efectos de los fármacos , Ácido Acético/farmacología , Ácido Acético/uso terapéutico , Infecciones por Acinetobacter/prevención & control , Acinetobacter baumannii/crecimiento & desarrollo , Antibacterianos/uso terapéutico , Biopelículas/crecimiento & desarrollo , Quemaduras/microbiología , Clorhexidina/farmacología , Clorhexidina/uso terapéutico , Miel , Técnicas In Vitro , Yodo/farmacología , Yodo/uso terapéutico , Pruebas de Sensibilidad Microbiana , Poliésteres/uso terapéutico , Polietilenos/uso terapéutico , Infecciones por Pseudomonas/prevención & control , Pseudomonas aeruginosa/crecimiento & desarrollo , Plata/farmacología , Plata/uso terapéutico , Infección de Heridas/prevención & control
7.
Burns ; 40(5): 860-4, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24332438

RESUMEN

INTRODUCTION: Hydrotherapy is widely used in burns management however there are risks associated with its use, in particular cross-infection. Data regarding indications and techniques in common use is deficient. This study aimed to investigate hydrotherapy practices in the UK and Ireland. METHODS: A survey of the hydrotherapy practice of major burn care providers was performed by e mail and where necessary, follow up telephone contact. RESULTS: The survey included 28 burn care providers. 27 reported using hydrotherapy. Only 11 (41%) had defined indication criteria with 4 (15%) implementing a specific protocol. Variations in hydrotherapy practice were seen. CONCLUSION: Hydrotherapy is used nationwide, however considerable variation in practice exists. One area worthy of further consideration is the need for appropriate standards of infection control.


Asunto(s)
Quemaduras/rehabilitación , Infección Hospitalaria/prevención & control , Hidroterapia/métodos , Control de Infecciones/métodos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Infección de Heridas/prevención & control , Humanos , Irlanda , Selección de Paciente , Reino Unido
8.
BMJ Open ; 4(11): e006278, 2014 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-25371418

RESUMEN

OBJECTIVES: Pseudomonas aeruginosa is a common nosocomial pathogen responsible for significant morbidity and mortality internationally. Patients may become colonised or infected with P. aeruginosa after exposure to contaminated sources within the hospital environment. The aim of this study was to determine whether whole-genome sequencing (WGS) can be used to determine the source in a cohort of burns patients at high risk of P. aeruginosa acquisition. STUDY DESIGN: An observational prospective cohort study. SETTING: Burns care ward and critical care ward in the UK. PARTICIPANTS: Patients with >7% total burns by surface area were recruited into the study. METHODS: All patients were screened for P. aeruginosa on admission and samples taken from their immediate environment, including water. Screening patients who subsequently developed a positive P. aeruginosa microbiology result were subject to enhanced environmental surveillance. All isolates of P. aeruginosa were genome sequenced. Sequence analysis looked at similarity and relatedness between isolates. RESULTS: WGS for 141 P. aeruginosa isolates were obtained from patients, hospital water and the ward environment. Phylogenetic analysis revealed eight distinct clades, with a single clade representing the majority of environmental isolates in the burns unit. Isolates from three patients had identical genotypes compared with water isolates from the same room. There was clear clustering of water isolates by room and outlet, allowing the source of acquisitions to be unambiguously identified. Whole-genome shotgun sequencing of biofilm DNA extracted from a thermostatic mixer valve revealed this was the source of a P. aeruginosa subpopulation previously detected in water. In the remaining two cases there was no clear link to the hospital environment. CONCLUSIONS: This study reveals that WGS can be used for source tracking of P. aeruginosa in a hospital setting, and that acquisitions can be traced to a specific source within a hospital ward.


Asunto(s)
Infección Hospitalaria/microbiología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/genética , Adulto , Femenino , Genoma Bacteriano , Estudio de Asociación del Genoma Completo , Hospitales , Humanos , Masculino , Estudios Prospectivos
10.
Curr Genet ; 54(2): 83-94, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18622616

RESUMEN

The novel yeast protein Tar1p is encoded on the anti-sense strand of the multi-copy nuclear 25S rRNA gene, localizes to mitochondria, and partially suppresses the mitochondrial RNA polymerase mutant, rpo41-R129D. However, the function of Tar1p in mitochondria and how its expression is regulated are currently unknown. Here we report that Tar1p is subject to glucose repression and is up-regulated during post-diauxic shift in glucose medium and in glycerol medium, conditions requiring elevated mitochondrial respiration. However, Tar1p expression is down-regulated in response to mitochondrial dysfunction caused by the rpo41-R129D mutation or in strains lacking respiration. Furthermore, in contrast to the previously reported beneficial effects of moderate over-expression of Tar1p in the rpo41-R129D strain, higher-level over-expression exacerbates the ROS-derived phenotypes of this mutant, including decreased respiration and life span. Finally, two-hybrid screening and in vitro-binding studies revealed a physical interaction between Tar1p and Coq5p, an enzyme involved in synthesizing the mitochondrial electron carrier and antioxidant, coenzyme Q. We propose that Tar1p expression is induced under respiratory conditions to maintain oxidative phosphorylation capacity, but that its levels in mitochondria are typically low and stringently controlled. Furthermore, we speculate that Tar1p is down-regulated when respiration is defective to prevent deleterious ROS-dependent consequences of mitochondrial dysfunction.


Asunto(s)
Respiración de la Célula/genética , ADN Ribosómico/metabolismo , Mitocondrias/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , ADN Ribosómico/genética , Proteínas Mitocondriales , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA